Skip to main content
CVSACovista Inc.Sell5.4·$115.84+0.62%
SellModerate Confidence
Investment thesis

Covista screens attractively valued at a forward P/E of 13.2 times and a PEG of 0.88, underpinned by four consecutive earnings beats averaging more than 11% above consensus; the chief offset is negative price momentum that has not cleared the minimum threshold, keeping the entry setup cautious despite sound fundamentals.

Thesis pillars

  • Negative Momentum Near Term HeadwindStable
  • Attractive Forward Valuation Low PegStable
  • Solid Piotroski Financial HealthStable
  • +1 more pillar — see the Why tab for full reasoning

Full reasoning →

Open full analysis

Covista Inc. (CVSA) Stock Analysis

Catalyst-Driven edge

SellVALUE-TRAP 1/5QualityModerate Confidence

Consumer Defensive · Education & Training Services

Sell if holding. Momentum 4.3/10 is below the 5.0 floor at $115.84 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Weak growth.

Adtalem is the leading healthcare educator in the U.S. and a systemically important solution for preparing a diverse talent workforce that meets the needs of the healthcare industry. The purpose of Adtalem is to empower students to achieve their goals, find success, and make... Read more

$115.84+14.7% A.UpsideScore 5.4/10#13 of 18 Education & Training Services
QualityF-score7 / 9FCF yield6.97%
Stop $107.73Target $132.81(analyst − 15%)A.R:R 1.5:1
Analyst target$156.25+34.9%4 analysts
$132.81our TP
$115.84price
$156.25mean
$175

Sell if holding. Momentum 4.3/10 is below the 5.0 floor at $115.84 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Weak growth. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.4/10, moderate confidence.

Passes 6/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.

TrendMatrix Research · upcoming catalyst calendar

Upcoming dated catalysts

Thu, Aug 6, 202612d to earnings· next earnings call

Thesis

Rewards
Strong earnings beat streak (4/4)
Attractive valuation
Risks
Weak growth

Key Metrics

P/E (TTM)16.7
P/E (Fwd)13.0
Mkt Cap$3.9B
EV/EBITDA10.7
Profit Mgn12.3%
ROE17.9%
Rev Growth4.5%
Beta0.62
DividendNone
Rating analysts10

Quality Signals

Piotroski F7/9MoatNarrow

Options Flow

P/C0.67bullish
IV63%elevated

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

Rating Breakdown

1 floor-breaker

Growth below the gate floor. Component breakdown shows what dragged the score down.static

Earnings Growth
0.0
Revenue Growth
3.6
GatesMomentum 4.3<4.5EARNINGS PROXIMITY 12d<=14d (soft)A.R:R 1.5 ≥ 1.5Insider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARSuitability: Aggressive
RSI
35 · Neutral
20D MA 50D MA 200D MAGOLDEN CROSSSupport $109.42Resistance $135.96

Price Targets

$108
$133
A.Upside+14.7%
A.R:R1.5:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeSteady

Risk Alerts

! momentum at 4.3 (below the engine's 4.5 threshold)

Earnings

B
B
B
B
4/4 beats
Next Earnings2026-08-06 (12d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is CVSA stock a buy right now?

Sell if holding. Momentum 4.3/10 is below the 5.0 floor at $115.84 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Weak growth. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $107.73. Score 5.4/10, moderate confidence.

What is the CVSA stock price target?

Take-profit target: $132.81 (+14.7% upside). Prior stop was $107.73. Stop-loss: $107.73.

What are the risks of investing in CVSA?

Weak growth.

Is CVSA overvalued or undervalued?

Covista Inc. trades at a P/E of 16.7 (forward 13.0). TrendMatrix value score: 7.4/10. Verdict: Sell.

What do analysts say about CVSA?

10 analysts cover CVSA with a consensus score of 4.3/5. Average price target: $156.

What does Covista Inc. do?Adtalem is the leading healthcare educator in the U.S. and a systemically important solution for preparing a diverse...

Adtalem is the leading healthcare educator in the U.S. and a systemically important solution for preparing a diverse talent workforce that meets the needs of the healthcare industry. The purpose of Adtalem is to empower students to achieve their goals, find success, and make inspiring contributions to our global community.

Related stocks: TAL (TAL Education Group) · EDU (New Oriental Education & Techno) · PXED (Phoenix Education Partners, Inc) · PRDO (Perdoceo Education Corporation) · LAUR (Laureate Education, Inc.)
Home Stocks CVSA

Latest news

Latest News

Newser88d ago
MSN74d ago
Yahoo Finance74d ago
StockStory81d agoEarnings
Yahoo Finance75d ago
Yahoo Finance75d ago
CDLLife82d ago
FreightWaves87d ago
Yahoo Finance73d ago
StockStory79d ago
TradingView79d ago
Marketscreener.com79d agoEarnings
Marketscreener.com80d agoEarnings
Business Wire80d agoEarnings
Investing.com South Africa80d agoEarnings
Simplywall.st77d ago
Timothysykes.com77d ago
GuruFocus99d ago
Timothysykes.com78d agoProduct
GuruFocus78d ago
Loading more...